Opzelura® (Ruxolitinib) Cream Becomes First Steroid-Free Topical Jak Inhibitor Approved In The European Union For Adults With Moderate Atopic Dermatitis
INCY•European Union approval for Opzelura
July 29 (Reuters) - Incyte Corp INCY.O:
- Opzelura® (ruxolitinib) cream becomes first steroid-free topical JAK inhibitor approved in the European Union for adults with moderate atopic dermatitis
- Incyte - European Commission approves Opzelura (ruxolitinib) cream for moderate atopic dermatitis in adults
Source text: ID:nBw88YmC1a
Further company coverage: INCY.O
Related News
Royal Caribbean Group <RCL.N>: BofA Global Research raises price objective to $330.00 from $310.00
RCL•
Lighthouse Canton says memory-chip selloff diverges from earnings, flags opportunity to sell elevated volatility
SOXX•
